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Receiver operator characteristic (ROC) 
analysis illustrates that a CTXD score 
cut point of 1.1 results in a sensitivity of 
0.91 and a specificity of 0.58, using the 
Center for Epidemiological Studies 
Depression (CESD) standard cut point 
of 16. This indicates that the CTXD 
captures nearly all the cases of 
depression on the CESD (sensitivity) 
while also identifying elevated distress 
that is distinct from depression 
(specificity). 
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A cancer diagnosis is never an easy challenge, and the distress that follows is often fluctuating but 
enduring. It adversely affects the well-being of cancer patients from the initial finding, through 
treatment and follow-up to survivorship or end of life. This cancer-related stress impacts not only 
overall quality of life, but also satisfaction with medical care and adherence to treatment 
recommendations. Some studies have even demonstrated decreased survival rates with increased 
stress levels. The evidence for distress monitoring is compelling, but current standardized measures 
of anxiety and clinical depression account poorly for the wide-ranging complexity of cancer-related 
emotions. 
Because of the high risk of long-term complications and death after hematopoietic cell 
transplantation (HCT), efforts have been made to evaluate the associated distress using a number of 
existing measures. However, one single, non-duplicative, non-overlapping measure that captures all 
important aspects for understanding cancer-related distress within one test would more likely provide 
a useful tool for routine screening. With this in mind, Drs. Karen Syrjala, Jean Yi, and Shelby Langer 
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from the Clinical Research Division set out to define a reliable and valid distress measure for HCT-
treated cancer patients. Importantly, the measure needed to be minimally burdensome to patients. 
"To be useful in research or clinical care, it is important to be brief but relevant to people's 
experiences," Dr. Syrjala explained. The development and psychometric properties of the resulting 
Cancer and Treatment (CTXD) measure was recently published in Psycho-Oncology. 
Potentially stressful aspects were revealed through qualitative interviews with 48 transplant 
recipients regarding feelings about the disease and related treatment, starting at the point before 
HCT when most transplant recipients experience peak distress. The first CTXD version comprised 
46 items that were iteratively selected based on feedback from patients and additional input from 
physicians, nurses, and other healthcare providers. A cohort of 176 patients from 8 transplant 
centers then completed the baseline CTXD, along with other measures, and after statistical analysis 
the initial 46 items were reduced to 22. In this optimized version, 6 factors were distinguished that 
explained 69% of the variance in distress between patients: uncertainty, health burden, identity, 
medical demands, finances, and family strain. The tradeoff between sensitivity (true positive) and 
specificity (true negative) for identifying elevated distress was described through receiver operating 
characteristic (ROC) analysis. A large majority of cases of elevated depression, defined by the 
Center for Epidemiologic Studies Depression (CESD) scale, were captured by a CTXD score > 1.1 
(sensitivity rate 91%). High-distress cases lacking parallel elevated depression were also identified 
(specificity 58%), indicating that the measured qualities of distress extended beyond depression. 
The investigators hope that the new measure will improve the screening of distress among cancer 
patients for both research and clinical care, thereby expediting decisions about psychosocial 
interventions. "The measure can replace the screening of depression and anxiety separately, since it 
evaluates those aspects of clinical need, but also help to identify those patients needing 
psychosocial care for issues that might not be about clinical depression or general anxiety. Fear of 
recurrence, living with uncertainty about the future, and worry about finances and family are ever-
present concerns for lots of people after a cancer diagnosis," Dr. Syrjala explained. Ideally, clinicians 
could use the information to personalize patient referral needs. "The bottom line goal is to use the 
routine assessment of distress to improve the care of our patients so they not only get a referral for 
psychosocial care when needed, but a referral to the right resources at the right time for them," she 
concluded. 
The CTXD is not specific for HCT and may therefore also be useful in other settings. After having 
studied the measure over time after HCT, the team has proceeded with CTXD data collection from 
other cancer patients as well. The correlations found so far among different patient groups have 
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been quite surprising, according to Dr. Syrjala. "None of the items we needed were specific to the 
HCT experience, but were shared by patients with other cancers - like thoughts about dying or how 
the family would get through treatment and recovery." 
Still, much remains to be investigated. Can the CTXD help predict who is at greater risk of poor 
outcomes during or after treatment? Will treatment improve the distress indicated by the CTXD? The 
researchers have many hypotheses to test before the full potential of the new distress measure is 
revealed. Hopefully, they are not too stressed out about it. 
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